The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. [electronic resource]
Producer: 19930125Description: 795-8 p. digitalISSN:- 0364-5134
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.